Vibeke Strand | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Hoda Salem | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Hoda Salem | Clinical Trials | Best Researcher Award

Prof. Dr. Hoda Salem, University of Tabuk, Saudi Arabia

Prof. Dr. Hoda Salem 🎓 is a distinguished clinical pharmacy expert with a Ph.D. in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. With over two decades of academic and clinical experience, she currently serves as Professor at Tabuk University, Saudi Arabia 🇸🇦. She has led numerous funded research projects, particularly in neuropharmacology and pharmacogenetics 🧬🧠. A prolific scholar, Dr. Salem has published in Q1 journals 📚 and actively mentors Ph.D. and MSc students. Her contributions extend to curriculum development, hospital training, and quality assurance in education 🌍. She’s a driving force in pharmacy education and clinical research excellence.

Publication Profile

Google Scholar

Education

Prof. Dr. Hoda Salem 🎓 earned her Bachelor’s degree in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. She continued her academic journey with a Master’s degree (M.Sc.) in Clinical Pharmacy from the same university, demonstrating early on her commitment to specialized healthcare and pharmaceutical practice 💊. Her pursuit of excellence culminated in a Ph.D. in Clinical Pharmacy in 2008 🧪, also from Tanta University. This strong academic foundation laid the groundwork for her impactful career in clinical pharmacy, education, and research, making her a respected figure in both Egyptian and international pharmaceutical education and clinical advancement.

Experience

Prof. Dr. Hoda Salem ⚕️ has made significant contributions to both scientific and clinical work in pharmacy education and healthcare. She played a pivotal role in quality assurance and accreditation by leading the self-study efforts and contributing to strategic planning at Tabuk and Al-Azhar Universities 📊📚. As a committee member, she helped supervise undergraduate examinations and mentored numerous Ph.D. and M.Sc. research projects 🎓🧬. Her clinical work includes patient counseling, drug dispensing, and providing accurate drug information to healthcare professionals at Tanta University Hospitals 💊🏥, reinforcing her commitment to enhancing both education and patient care.

Research Focus

Prof. Dr. Hoda Salem’s 🧪 research focus lies in clinical pharmacy, pharmaceutics, and neuropharmacology with a multidisciplinary approach integrating nanotechnology, drug delivery systems, and natural compounds. Her publications explore the treatment of diseases such as Alzheimer’s 🧠, Parkinson’s, ADHD, and fungal infections, along with oncology 🧬 and pharmacogenetics in breast cancer therapy. She has also worked on innovative therapies like solid lipid nanoparticles, niosomal gels, and bone marrow stem cell applications. Her clinical trials and lab studies reflect a deep commitment to therapeutic innovation, patient care, and translational research 💊🔬, bridging pharmaceutical science and clinical outcomes for better healthcare.

Publication Top Notes

Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study‏

Neuroprotective effects of phytochemicals against aluminum chloride-induced Alzheimer’s disease through ApoE4/LRP1, wnt3/β-catenin/gsk3β, and TLR4/NLRP3 pathways with physical …‏

Neuroprotective effect of morin hydrate against attention-deficit/hyperactivity disorder (ADHD) induced by MSG and/or protein malnutrition in rat pups: Effect on oxidative …‏

Autologous transplantation of CD34+ bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia‏

A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major‏

The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy‏

Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients‏

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major‏

Formulation, in-vitro and in-vivo evaluation of nystatin topical gel‏

DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA‏

Effect of oral Methyl Prednisolone on different radiological patterns of hypersensitivity pneumonitis‏

Claudia Omes | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Claudia Omes | Clinical Trials | Best Researcher Award

Dr Claudia Omes, Fondazione IRCCS Policlinico San Matteo, Italy

Dr. Claudia Omes is a distinguished biologist specializing in reproductive medicine, embryology, and stem cell research. She holds multiple degrees from the University of Pavia and Milan, including a Ph.D. in Bioengineering and Bioinformatics. Dr. Omes is the Head Biologist and Lab Director at the Center for Reproductive Medicine at Policlinico “San Matteo,” Pavia, and a Contract Professor at the University of Pavia. She has contributed to pioneering research in cryopreservation, semen analysis, and stem cell biology, with multiple publications in top journals. She is an active member of ESHRE and SIERR. 🧬🔬👩‍🔬📚

Publication Profile

Orcid

Qualifications and Certifications

Dr. Claudia Omes is a distinguished expert in bioengineering and bioinformatics, holding a Ph.D. in the field, along with a Postgraduate degree in Microbiology and Virology, both achieved with high honors 🎓. She also holds multiple specialized certifications, including ISO 9001:2008 Certified Auditor in Public Health 🏅 and certifications in clinical embryology and semen analysis 🧬. Her expertise spans across bioengineering, public health, and clinical research, making her a prominent figure in the scientific community. Dr. Omes’ comprehensive academic background and specialized certifications highlight her commitment to advancing healthcare and biotechnology. 🌿💡

Research Experience

Dr. Claudia Omes is the Head Biologist and Lab Director at the Center for Reproductive Medicine of Fondazione I.R.C.C.S. Policlinico “San Matteo.” Her pioneering work in human reproduction and embryology has significantly advanced the field. She specializes in cryopreservation of spermatozoa, oocytes, and embryos, as well as in stem cell research and bone tissue engineering. Through her dedication and expertise, Dr. Omes has made notable contributions to reproductive medicine, with a focus on improving fertility treatments and tissue regeneration. Her work continues to shape the future of reproductive science. 🧬🔬🍼👩‍🔬

Awards and Recognition

Dr. Claudia Omes has earned significant recognition in the scientific community. She was awarded the Best Oral Communication in the Biological Field at the II FISSR conference in Riccione (May 24-26, 2012) 🏅. In 2011, she received the GIC Study Award from the Italian Society of Cytometry at the XXIX National Conference of Cytometry in Salerno 🎖️. Dr. Omes was also honored with the Best Poster award at the 62nd National Congress of SIAI in Verona (September 14-16, 2008) 🎨. These accomplishments showcase her excellence in the fields of cytometry and biological sciences 🌱🔬.

Research Focus

Dr. Claudia Omes focuses on reproductive biology and male infertility, exploring factors that impact sperm quality and fertility. Her research investigates the role of infections, inflammation, and biomarkers in male fertility, particularly in infertile and oncological patients. She has contributed to studies on the effects of HPV infections (HPV-51 and HPV-52) on sperm quality, the expression of miRNAs in pre-implantation embryos, and the potential of novel diagnostic approaches like calprotectin to screen for male infertility risk. Additionally, Dr. Omes has studied the effects of cancer-induced inflammation on semen quality and the application of stem cells in reproductive medicine. 🧬👨‍🔬💉

Publication Top Notes

HPV-51 or HPV-52 Infection Could Impair Sperm Quality in Infertile Patients: A Preliminary Study on Our Experience from North-Western Italy

Expression of miRNA from spent pre-implantation embryos culture media

Human Ovarian Follicular Fluid Mesenchymal Stem Cells Express Osteogenic Markers When Cultured on Bioglass 58S-Coated Titanium Scaffolds

Calprotectin as a novel diagnostic approach to screen male infertility risk: A pilot study

Male fertility preservation: is there a role for cancer-induced inflammation that affects semen quality in oncological patients?

Myeloperoxidase and lactoferrin as possible inflammatory markers of an infertility risk?

Correction: MAGIC-factor 1, a partial agonist of MET, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis (PLoS ONE (2008) 3:9 (e3223) 10.1371/journal.pone.0003223)

 

 

Serefnur Ozturk | Clinical Trials | Women Researcher Award

Published on by Top Pharmaceutical

Serefnur Ozturk | Clinical Trials | Women Researcher Award

Prof Serefnur Ozturk, Selcuk University Faculty of Medicine, Turkey

Prof. Şerefnur Öztürk is a leading expert in Neurology and Neurointensive Care, currently serving as the Head of the Neurology Department at Selcuk University, Turkey. She has held prominent roles including Vice Dean of the Faculty of Medicine (1996-2020) and President of the Turkish Neurological Society (2014-2021). With significant international influence, she contributes to the European Academy of Neurology and World Stroke Organization. She has led pivotal projects and trials in stroke and COVID-19-related neurological care. Prof. Öztürk is an acclaimed researcher with numerous influential publications in neurology.

Publication Profile

scopus

Education

Prof. Serefnur Ozturk has an impressive educational background. She began her medical studies at Ankara University Medical Faculty, where she earned her degree between 1980 and 1987. Her academic journey continued with a prestigious NATO Fellowship at Arizona University’s Stroke Center in 1993, further enhancing her expertise. In 1998, she advanced her knowledge in neurology and intensive care at Pittsburgh University, where she studied in their renowned Neurology and Intensive Care Department. These experiences have shaped Prof. Ozturk into a leading figure in her field. 🏥🎓🧠

Internship and Residencies

Prof. Serefnur Ozturk completed her internship at Ankara University Medical Faculty, where she gained valuable hands-on experience. Following this, she pursued her residency at Ankara Numune Research and Education Hospital, further honing her medical skills. Prof. Ozturk’s dedication to her field is reflected in her board certification, earning the Turkish Neurological Board Council Certificate. This certification recognizes her extensive expertise in neurology, solidifying her status as a trusted professional in her area of specialization. Her journey through internships, residencies, and board certification showcases her commitment to excellence. 🏥💉🧑‍⚕️🧠

Experiences

Prof. Serefnur Ozturk holds numerous prestigious leadership roles in neurology. She served as the President of the Turkish Neurological Society from 2014 to 2021 and is currently a member of various important committees, including the European Academy of Neurology (EAN) COVID-19 Task Force and the World Stroke Organization Global Policy Committee. Additionally, she is the Vice President of the European Environmental Neurology Society and has held positions within the World Federation of Neurology (WFN), including President of the Migrant Neurology Specialty Group. Prof. Ozturk is dedicated to advancing stroke care, cerebrovascular diseases prevention, and diversity in neurology. 🧠🌍👩‍⚕️🏥

Projects

Prof. Serefnur Ozturk has played a pivotal role in several major clinical trials and registries. She is the Principal Investigator of the EAN ENERGY COVID-19 Registry and the ENSEMBLE study, showcasing her leadership in critical research. Additionally, Prof. Ozturk serves as the National Coordinator for the Turkish COVID-19 Registry, the ENOS Trial, and TICH-2. Her expertise extends to key studies like the PERFORM Study (Phase III), FACT (Phase IV), and NAVIGATE-ESUS, where she also holds significant leadership positions. Her contributions to clinical research have greatly impacted neurology and stroke care. 🔬🧠🌍💉

Research Focus

Prof. Şerefnur Öztürk’s research focus lies predominantly in neurology, with a special emphasis on the neurological impacts of COVID-19, ischemic stroke, and innovative prognostic tools like the Selcuk Score. Her work is pivotal in advancing the understanding of how pandemics influence neurological care and the management of post-pandemic risks. Additionally, Prof. Öztürk contributes to cutting-edge stroke prevention and rehabilitation technologies, including web-based solutions. Her contributions drive progress in neuro-COVID research, stroke management, and global neurological health policies, showcasing her commitment to improving outcomes for patients worldwide. 🌍🧠💻

Publication Top Notes

The European Academy of Neurology NeuroCOVID-19 Task Force: A lesson for the future

Muscle mass as a modifier of stress response in acute ischemic stroke patients

Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers — An updated European Academy of Neurology consensus statement

The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data from 121 Surgically Treated Participants from the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial

General neurology: Current challenges and future implications

Climate Change and Stroke: A Topical Narrative Review

Dvora Joseph Davey | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dvora Joseph Davey | Clinical Trials | Best Researcher Award 

Dr Dvora Joseph Davey, University of California, Los Angeles, UCLA, South Africa

Dr. Dvora Joseph Davey is a distinguished epidemiologist with a focus on infectious diseases, particularly HIV and STIs. Holding a Ph.D. in Epidemiology from UCLA, her research, mainly in sub-Saharan Africa, aims to reduce the burden of HIV through innovative interventions. As a Principal Investigator in clinical trials, Dr. Davey has contributed significantly to global HIV prevention efforts, especially for pregnant women. She is actively involved in policy-making with groups like the WHO and NIH, shaping global health initiatives. Her leadership, extensive research, and mentorship in global health make her an exemplary figure in public health. 🌍🔬💉

Publication Profile

google scholar

scopus

orcid

Education

Dr. Dvora Joseph Davey has an impressive academic background, beginning with a B.A. in International Affairs and French from the University of Colorado, Boulder, in 1998. She went on to earn a Master of Public Health (M.P.H.) in Population and Reproductive Health Sciences from Columbia University in 2003. Dr. Davey completed her Ph.D. in Epidemiology at the University of California, Los Angeles, in 2016, followed by a fellowship in Epidemiology of HIV at the University of North Carolina in 2017. She furthered her expertise with a postdoctoral fellowship in Global HIV Prevention at UCLA in 2018. 🌍📚

Scientific Appointments

Dr. Dvora Joseph Davey has held several prestigious positions throughout her career. Currently, she serves as an Associate Professor in Infectious Diseases and Epidemiology at UCLA’s School of Medicine and School of Public Health, respectively. She also holds honorary roles at the University of Cape Town and Desmond Tutu Health Foundation. Dr. Davey’s research includes being the Principal Investigator on a study about sexual behavior and PrEP acceptability. Her past positions include HIV Director at Population Services International in Mozambique and Director at the Rwanda-Emory HIV Research Group. With her diverse roles, Dr. Davey has had a significant global impact. 🌍🩺📊

Professional Memberships

Dr. Dvora Joseph Davey has made significant contributions to the field of HIV and reproductive health, serving as an Assistant Editor for renowned journals such as AIDS, JIAS, and PloS Global Health. She is also an active member of the South African Clinical Research Association and the American Public Health Association. Her honors include invitations to present at major conferences like HIVR4P 2024 in Peru and WHO Working Group meetings. Dr. Davey has co-chaired several influential research working groups, including on PrEP in pregnancy, and received multiple awards, including UCLA’s Epidemiology Department Summer Fellowship. 🌍📚🎤

Awards

Dr. Dvora Joseph Davey is a renowned researcher whose work focuses on HIV prevention and treatment, particularly in pregnant and breastfeeding women. Her studies address key challenges in high HIV incidence communities, especially in Sub-Saharan Africa. Dr. Davey investigates Pre-exposure Prophylaxis (PrEP) access, adherence, and effectiveness among pregnant women, emphasizing the need for female-controlled HIV prevention methods during vulnerable periods. Additionally, she explores the integration of STI testing, alcohol use, and the impact of intimate partner violence on HIV risk. Her contributions significantly influence HIV-related healthcare policies, aiming to reduce transmission and improve outcomes in these populations. 👩‍🔬🌍💉

Policy Involvement

Dr. Dvora Joseph Davey has made significant contributions to national and international HIV and STI policy-making. Her leadership in key working groups, including the National PrEP and Prevention of Vertical Transmission of HIV Working Groups, as well as the World Health Organization’s Working Group on Long-Acting PrEP in pregnancy, highlights her expertise and influence. These positions enable Dr. Davey to play a pivotal role in translating scientific research into actionable policies, ensuring her work impacts not only the scientific community but also global health policies. Her efforts amplify the reach of her research, making a lasting impact on public health worldwide. 🌍🩺💉

Leadership

Dr. Dvora Joseph Davey’s leadership in managing large-scale clinical trials and mentoring emerging public health and epidemiology professionals showcases her dedication to education and capacity-building in global public health. As a recipient of the prestigious NIH/Fogarty International Research Scientist Development Award (IRSDA) and the follow-on R01 award, Dr. Davey has solidified her position as a thought leader in the field. Her commitment to fostering continuous learning and improvement within the global health community reflects her deep influence and dedication to advancing public health practices worldwide. 🎓🌍💉👩‍🔬

Ongoing Projects

Dr. Dvora Joseph Davey’s ongoing research, supported by NIH and Gilead Corporation, plays a crucial role in addressing HIV within vulnerable populations. Her work on projects like PrEP-PP and SCOPE-PP, alongside innovative initiatives such as a community-based peer-led intervention to tackle alcohol use and HIV risk in pregnant women, highlights her proactive approach to solving complex public health challenges. Dr. Davey’s research aims to create effective, targeted solutions that address the unique needs of at-risk communities, contributing significantly to advancing HIV prevention and care efforts. 💡🧑‍🔬🩺🌍

Research Focus

Dr. Dvora Joseph Davey is a prominent researcher specializing in HIV prevention, sexually transmitted infections (STIs), and maternal health. Her work focuses on pre-exposure prophylaxis (PrEP) for HIV, examining its safety and efficacy among pregnant and postpartum women. She also explores STI diagnostics, point-of-care testing, and the prevalence of curable STIs in low- and middle-income countries. Her research seeks to improve access to health interventions, particularly for vulnerable populations like men who have sex with men and transgender women. Dr. Davey’s contributions help shape public health strategies for HIV prevention and sexual health. 🦠💉

Publication Top Notes

 

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Dr. Minoo Moghimi at Mazandaran University of Medical Sciences,Iran

PROFILE  

Google scholar

 

Early Academic Pursuits 🎓

Minoo Moghimi embarked on her academic journey with a solid foundation in the National Organization for Development of Exceptional Talents, where she obtained her high school diploma in Yazd (2007-2011). This formative education laid the groundwork for her entrance into the field of pharmacy, where she pursued a PharmD at Yazd University of Medical Sciences from 2011 to 2018. Her early involvement with the faculty research committee highlighted her dedication to the field of pharmacotherapy, showcasing a keen interest in advancing pharmaceutical science right from the start.

Moghimi’s PharmD thesis focused on developing porous microencapsulated probiotics using a spray freeze drying technique. This innovative research emphasized the importance of drug formulation technology and aimed at enhancing probiotic viability. The success of this project led to a patent, marking a significant achievement in her early career and reflecting her capability to contribute meaningfully to pharmaceutical innovation.

Professional Endeavors 🏥

After completing her PharmD, Moghimi chose to channel her expertise into clinical applications by entering the Clinical Pharmacy Residency Program at Mazandaran University of Medical Sciences in 2018. This decision was driven by her passion for directly assessing drug effects in real-world patient scenarios. Throughout her residency, she demonstrated a profound dedication to clinical pharmacy, actively participating in research programs and engaging in numerous projects with a strong focus on clinical trials.

Her professional trajectory took a pivotal turn in 2020 during the COVID-19 pandemic when she contributed to the DISCOVER trial. This was a large-scale, randomized clinical trial involving over 1,000 patients, evaluating the efficacy of sofosbuvir and daclatasvir in treating hospitalized COVID-19 patients. The findings, published in the Journal of Antimicrobial Chemotherapy, were instrumental in understanding potential treatment options during the pandemic, reflecting her commitment to evidence-based clinical practice.

Moghimi’s professional expertise also extends beyond infectious diseases, as she has been involved in designing and implementing clinical trials in oncology, gynecology, and dentistry. Her diverse research portfolio underscores her adaptability and readiness to tackle multifaceted clinical challenges.

Contributions and Research Focus 📚

Minoo Moghimi’s primary research focus lies in managing chemotherapy-induced adverse effects, a critical area that significantly impacts cancer patient care. Her ongoing residency thesis, “Evaluation of the Efficacy and Safety of the Addition of Lacosamide to Duloxetine in the Treatment of Taxane-Induced Peripheral Neuropathy: A Randomized Double-Blind Placebo-Controlled Trial,” reflects this focus. Through this project, she aims to mitigate the debilitating side effects associated with chemotherapy, thus enhancing the quality of life for cancer patients.

In addition to her research in oncology, Moghimi has actively contributed to pharmacotherapy in critical care settings, clinical nutrition management, and drug-drug interaction management. Her ability to design comprehensive clinical trials is supported by her skills in clinical trial design, protocol development for critical medications, and medication reconciliation—skills that have proven vital in her multidisciplinary approach to patient care.

Moghimi’s contributions are not limited to clinical environments; she also engages in academic service. As a reviewer for respected journals like Pharmaceutical and Biomedical Research Journal (PBR) and Annals of Clinical and Medical Case Reports, she evaluates research, ensuring high standards in pharmacotherapy literature.

Accolades and Recognition 🏅

Throughout her academic and professional career, Minoo Moghimi has achieved several notable milestones. Her early achievement in patenting her thesis project during her PharmD studies reflects her commitment to innovation. During the COVID-19 pandemic, her role in the DISCOVER trial received significant recognition, as the study’s outcomes played a crucial role in informing clinical practices and treatment protocols for COVID-19 patients.

Impact and Influence 🌍

Minoo Moghimi’s research has had a tangible impact on the fields of clinical pharmacy and pharmacotherapy. Her work in chemotherapy-induced adverse effects, particularly taxane-induced peripheral neuropathy, aims to provide oncologists with better tools to manage the side effects of cancer treatments. By focusing on this critical aspect of cancer care, she is not only advancing research but also directly contributing to patient well-being, showcasing the transformative power of targeted pharmacotherapy.

Her involvement in critical care pharmacotherapy, nutrition management, and drug-drug interaction management demonstrates a holistic approach to patient care, where she considers various factors influencing therapeutic outcomes. This multidisciplinary expertise positions her as a key contributor to advancing patient-centered care in clinical settings.

Legacy and Future Contributions 🌟

Looking ahead, Minoo Moghimi aims to continue her work at the intersection of research and clinical practice. Her focus on chemotherapy-induced adverse effects, critical care, and nutrition management indicates a commitment to advancing patient care through evidence-based research. As a Board Certified Pharmacotherapy Specialist, her goal is to bridge the gap between research and clinical applications, ensuring that pharmacotherapy evolves in response to patient needs.

In the future, Moghimi plans to expand her research into novel drug therapies, aiming to develop innovative interventions for managing complex clinical conditions. Her dedication to the peer-review process reflects her intention to contribute to the scientific community by ensuring the dissemination of accurate and impactful research findings.

Skills and Technological Expertise 💻

Minoo Moghimi possesses a diverse skill set encompassing clinical trial design, research management, and critical care pharmacotherapy. Her expertise extends to protocol development for high-risk drugs, clinical nutrition, and drug-drug interaction management. In terms of technical skills, she is proficient with software like GraphPad Prism, Endnote, and MS Office—tools that are essential for managing data, conducting statistical analysis, and organizing research findings.

Research Interests and Aspirations 🔬

Her primary research interests revolve around chemotherapy-induced adverse effects, a field that holds immense potential for improving cancer care outcomes. Moghimi is also dedicated to critical care pharmacotherapy and nutrition management, fields where she hopes to make significant contributions in the future. Her aspiration is to develop strategies and guidelines that healthcare professionals can utilize to optimize treatment outcomes in complex clinical scenarios.

Conclusion 🎯

Minoo Moghimi’s journey from a dedicated pharmacy student to a Board Certified Pharmacotherapy Specialist is marked by a strong academic foundation, substantial research contributions, and a commitment to improving patient care. Her work has already left an indelible mark on the clinical pharmacy landscape, and her ongoing projects promise to further enhance therapeutic approaches in critical care and oncology. Moghimi’s career is a testament to the profound impact that dedicated research, clinical expertise, and a patient-centered approach can have in advancing healthcare.

🎓Publication 

A Narrative Review on Adverse Effects of Dasatinib With a Focus on Pharmacotherapy of Dasatinib-Induced Pulmonary Toxicities

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar
  • Journal    :Blood Research
  • Year         :2021

Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)

  • Authors   : Sara Mobarak, Mehdi Salasi, Ahmad Hormati, Javad Khodadadi, Masood Ziaee, Farshid Abedi, Azadeh Ebrahimzadeh, Zohreh Azarkar, Fariborz Mansour-Ghanaei, Farahnaz Joukar, Sara Yeganeh, Tofigh Yaghubi Kalurazi, Mohammadreza Naghipour, Zeinab Mehrabi, Amir Reza Bahadori, Shoeleh Yaghoubi, Rohollah Moslemi, Hamideh Abbaspour Kasgari, Hafez Fakheri, Minoo Moghimi, Amir Mohammad Shabani, Zahra Nekoukar, Farhang Babamahmoodi, 
  • Year         :2025

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with moderate COVID-19, A

  • Authors   :Zahra Nekoukar , Shahram Ala, Siavash Moradi, Andrew Hill, Ali Reza Davoudi Badabi, Ahmad Alikhani, Shahriar Alian, Minoo Moghimi, Amir Mohammad Shabani, Hamideh Abbaspour Kasgari
  • Journal    :Iranian Journal of Pharmaceutical Research
  • Year         :2021

Suicide attempt using zinc phosphide rodenticide: A case report and literature review

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Kimia Rasouli, Aref Hoseini, Zakaria Zakariaei, Rabeeh Tabaripour, Mahdi Fakhar, Elham Sadat Banimostafavi 
  • Journal    : Clinical case reports
  • Year         :2021

Prevalence of Thromboembolic Events, Including Venous Thromboembolism and Arterial Thrombosis, in Patients with COVID-19: A Systematic Review with Meta-Analysis

  • Authors   :Babak Bagheri, Abbas Alipour, Mojtaba Yousefi, Rozita Jalalian, Minoo Moghimi, Mahsa Mohammadi, Negar Hassanpour, Mohammadreza Iranian
  • Journal    :Tehran University of Medical Sciences
  • Year         :2023

Assist Prof Dr. AYŞEGÜL KILIÇLI|Clinical Trials| Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof Dr. AYŞEGÜL KILIÇLI|Clinical Trials |Best Researcher Award|

Assist Prof Dr. AYŞEGÜL KILIÇLI at mus alparslan university, Turkeys

PROFILE  

scopus

Orcid

 

Early Academic Pursuits 🎓

Assist. Prof. Dr. Ayşegül KILIÇLI embarked on her academic journey with a profound dedication to the field of nursing, focusing specifically on obstetrics and gynecology. She earned her Bachelor’s degree in Nursing from a reputable institution, where her commitment to the healthcare field began to shine. Driven by a desire to enhance her expertise and contribute significantly to her field, she pursued a Master’s degree in Obstetric and Gynecology Nursing. This was followed by rigorous research and a doctoral degree (Ph.D.) in the same domain, equipping her with advanced knowledge and research skills essential for a successful academic and professional career.

Professional Endeavors 👩‍⚕️

Dr. KILIÇLI is currently serving as an Assistant Professor in the Obstetric and Gynecology Nursing Department at Muş Alparslan University Health Sciences Faculty. Her role involves teaching, mentoring, and guiding students through their academic and clinical experiences. Her professional journey reflects a commitment to advancing nursing education and practice. She is actively involved in several research projects and has published extensively in high-impact journals. Her work focuses on improving healthcare practices and patient outcomes, particularly in the field of obstetrics and gynecology.

Contributions and Research Focus 🔬

Dr. KILIÇLI’s research is primarily concentrated on obstetric and gynecology nursing. One of her notable completed research projects is a randomized controlled trial examining the effect of neurolinguistic programming and progressive muscle relaxation exercises on breastfeeding success and self-efficacy. This innovative study has been instrumental in advancing knowledge about non-pharmacological interventions in maternal care. Her research contributions are reflected in her publications in SCI-E journals, where her work is highly regarded by the scientific community.

Accolades and Recognition 🏆

Dr. KILIÇLI’s research excellence and contributions to the field have earned her recognition in various forums. Her work has been cited in prestigious databases, including Science Citation Index-Expanded (SCI-E), Scopus, and Web of Science (ESCI). She is celebrated for her significant contributions to advancing obstetric and gynecology nursing practices. Her role as a corresponding researcher further highlights her leadership and expertise in the field, establishing her as a respected figure in the global research community.

Impact and Influence 🌍

Dr. KILIÇLI’s impact extends beyond her research and academic contributions. Her work has positively influenced clinical practices, particularly in improving breastfeeding outcomes and maternal self-efficacy. By integrating innovative approaches into her research, she has contributed to the development of more effective strategies in nursing care. Her influence is also evident in the academic and professional growth of her students, who benefit from her extensive knowledge and mentorship.

Legacy and Future Contributions 🔮

As a pioneering researcher in obstetric and gynecology nursing, Dr. KILIÇLI is poised to leave a lasting legacy in her field. Her dedication to advancing maternal and child health through research and education is commendable. Looking ahead, Dr. KILIÇLI plans to continue her research with a focus on exploring new interventions and improving existing practices. Her future contributions are expected to further enhance nursing care practices and patient outcomes, reinforcing her position as a leading expert in her field.

🎓Publication 

The effect of neurolinguistic programming and progressive muscle relaxation exercises on breastfeeding success and breastfeeding self-efficacy: A randomized controlled trial

  • Authors   :Kiliçli, A., Gül, S.
  • Journal    :Explore
  • Year         :2024

Effect of Reflexology on Pain, Fatigue, Sleep Quality, and Lactation in Postpartum Primiparous Women After Cesarean Delivery: A Randomized Controlled Trial

Stress, Anxiety, and Postpartum Depression in Parents with Premature Infants in Neonatal Intensive Care Unit

Stigmatizing attitudes, beliefs, and actions of women towards abortion in rural regions with high fertility

Women’s reproductive behaviour and perspectives on fertility, and their modifying factors, in a Turkish province with a high fertility rate